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Abstract
Background Ragweed pollen sensitivity is a common cause of allergic rhinitis (AR) worldwide. AR symptoms include itchy 
and runny eyes, sneezing, blocked nose, impaired sleep and social and emotional problems, which can have a significant 
impact on quality of life.
Objective The objective of this analysis was to estimate utilities for two pooled standardised quality (SQ) ragweed sublingual 
immunotherapy (SLIT) tablet trials by applying a previously developed mapping algorithm. This study validated the algorithm 
and extended its application to ragweed seasonal allergy trials. The mapping algorithm relates disease-specific quality-of-life 
scores to preference-based utilities that may be used to calculate quality-adjusted life-years (QALYs) in cost-effectiveness studies.
Methods A mapping algorithm based on a grass pollen allergy immunotherapy trial, GT-08 (EudraCT no. 2004-000083-27) 
was applied to pooled data from two ragweed pollen immunotherapy trials, P05233 (EudraCT 2008-003863-38) and P05234 
(EudraCT 2008-003864-20) to generate EuroQoL 5-Dimensions, 3-Levels (EQ-5D-3L) utilities from Rhinoconjunctivitis 
Quality of Life Questionnaire (RQLQ) data.
Results The mean utility difference between the SQ ragweed SLIT tablet and placebo was 0.025 [95% confidence interval 
(CI) 0.011–0.038]. The SQ ragweed SLIT tablet showed an incremental quality-adjusted life-days (QALDs) benefit of 1.900 
(95% CI 0.835–2.916) over 75 days.
Conclusions Application of a previously developed mapping function allowed for the calculation of QALDs associated with 
the SQ ragweed SLIT tablet. The results showed a QALD benefit of the SQ ragweed SLIT tablet in P05233 and P05234 
trials in the treatment of ragweed pollen-induced AR.
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Key Points for Decision Makers 
This study validated a Rhinoconjunctivitis Quality 
of Life Questionnaire (RQLQ) mapping function and 
extended its application to ragweed seasonal allergy 
trials.
The standardised quality (SQ) ragweed SLIT tablet 
provides quality-of-life benefits to patients with ragweed 
pollen-induced allergic rhinitis.
1 Introduction
Ragweed is an invasive flowering plant that originated 
in North America and spread worldwide. Ragweed sen-
sitivity affects 15–26% of the population in the USA. In 
Europe, clinically relevant ragweed pollen sensitisation 
has a prevalence of 11% among referrals to allergy special-
ists and is a common cause of allergic rhinitis (AR) and 
asthma [1–4]. The symptoms of AR include itchy eyes, 
runny eyes, sneezing, blocked nose and impaired sleep, as 
well as social and emotional problems [5]. These symp-
toms significantly impact on patient quality of life [1, 6, 7]. 
Patients often require additional general practice services 
and medication, which can be a financial burden [6–8].
AR may be treated by allergen avoidance, symptom-
relieving medications and allergy immunotherapy (AIT). 
Symptomatic medications include antihistamines, intra-
nasal glucocorticoids and leukotriene receptor antago-
nists. However, symptomatic medications do not target 
the underlying disease process causing the allergy, so 
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treatment must be administered repeatedly for as long 
as patients experience symptoms, which can be for life 
[9]. AIT is a disease-modifying therapy that induces a 
long-term immune tolerance that benefits quality of life 
for years after treatment discontinuation [1, 10]. AIT 
contains allergen extracts from the target allergen and 
may be administered subcutaneously or sublingually [1, 
11, 12]. The standardised quality (SQ) ragweed sublin-
gual immunotherapy (SLIT) tablet is a convenient and 
evidence-based alternative to subcutaneous AIT, as it can 
be administered at home and has demonstrated efficacy in 
the treatment of ragweed pollen-induced AR. The at-home 
administration makes SLIT tablets a cost-saving alterna-
tive for the healthcare sector [13].
The effect of AR on quality of life may be assessed using 
preference-based measures (PBMs) or disease-specific 
measures. Generic PBMs assess general quality of life with 
standardised dimensions broad enough to capture quality-of-
life differences in most disease areas. PBM responses may 
be used to generate health state utilities, which are relative 
preference weights for different health states measured on a 
cardinal scale and may be used to calculate quality-adjusted 
life-years (QALYs), a common outcome in cost-effective-
ness studies [14, 15]. Disease-specific measures of quality 
of life such as the Rhinoconjunctivitis Quality of Life Ques-
tionnaire (RQLQ) have the advantage of greater sensitivity 
to condition-specific symptoms but may not be used to cal-
culate QALYs [14–17].
When PBMs are not used in a clinical trial, it is possible 
to ‘map’ disease-specific quality-of-life scores to prefer-
ence-based utilities that may be used to calculate QALYs 
in cost-effectiveness studies [16, 17]. In a previous study, 
we developed a mapping algorithm based on a grass pollen 
immunotherapy trial and applied the algorithm to a tree 
pollen immunotherapy trial in order to estimate utilities 
and quality-adjusted life-days (QALDs) [18]. In this study, 
we applied the algorithm to data pooled from two SQ rag-
weed SLIT tablet trials to estimate utilities and QALDs 
because PBM data were not collected.
2  Methods
2.1  Clinical Trials
The mapping algorithm was developed based on a grass pol-
len allergy immunotherapy trial, GT-08 (EudraCT no. 2004-
000083-27) [19]. This trial was a randomised, double-blind, 
placebo-controlled, 5-year phase III trial designed to assess 
the efficacy and safety of the SQ grass SLIT tablet to treat 
AR in subjects with seasonal grass pollen allergy [9, 18]. 
The grass pollen season was defined between the first of 
three consecutive days and the last day of the last occurrence 
of three consecutive days with pollen count ≥ 10 grains/m3. 
In total, 634 adults with a clinical history of grass pollen-
induced AR with moderate to severe symptoms despite phar-
macotherapy use were randomised to active treatment plus 
pharmacotherapy or placebo plus pharmacotherapy. Subjects 
were asked to complete a daily record of AR symptoms and 
medication use in an electronic diary. The six recorded AR 
symptoms were runny nose, blocked nose, sneezing, itchy 
nose, itchy eyes and watery eyes. The three recorded asthma 
symptoms were cough, wheeze and shortness of breath. 
Subjects scored these symptoms on a scale from zero to 
three (0 = none, 1 = mild, 2 = moderate, 3 = severe). The AR 
symptom scores were added to generate the ‘daily symp-
tom score’, and the asthma scores were added to create the 
‘asthma symptom score’. Daily medication use was meas-
ured on a scale from 0 to 36 according to the type and dos-
age of medication used [19]. Throughout the trial, subjects 
had access to symptom-relieving medications, including 
desloratadine, olopatadine, budesonide and prednisone. Sub-
jects were also asked to complete two quality-of-life instru-
ments every week: the three-level EuroQoL 5-Dimensions 
(EQ-5D-3L) and the RQLQ [20].
The EQ-5D is a common PBM recommended by the 
UK National Institute for Health and Care Excellence for 
estimation of health state utilities. It measures quality of 
life in five dimensions: mobility, self-care, usual activi-
ties, pain/discomfort and anxiety/depression [21]. This 
study used the EQ-5D-3L instrument, and index values 
were derived from the UK value set [22]. The RQLQ is a 
disease-specific questionnaire consisting of 28 questions 
in seven domains: activity limitation, sleep problems, 
nose symptoms, eye symptoms, non-nose/eye symptoms, 
practical problems and emotional function. Subjects rated 
their health in these dimensions on seven levels (0 = no 
impairment, 6 = severe impairment) [23].
In this study, we applied the previously developed 
mapping algorithm to pooled data from two SQ ragweed 
SLIT tablet trials, P05233 and P05234, to calculate utili-
ties and QALDs. The SQ ragweed SLIT tablet trials were 
pooled to increase the sample size and statistical power 
of the data. Pooling the trials was appropriate in this case 
because the trials were identical in terms of active treat-
ment, population, treatment period, data collection and 
outcomes of interest. The primary difference between 
the studies was the location of the treatment sites, and 
the associated difference in pollen counts. However, the 
average pollen counts were similar between the two tri-
als. The mean pollen count during the P05233 trial was 
127 grains/m3, and the average pollen count during the 
P05234 trial was 122 grains/m3.
The P05233 trial evaluated the safety and efficacy of 
the SQ ragweed SLIT tablet (SCH 39641) compared with 
placebo for the treatment of AR in subjects with seasonal 
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ragweed allergies [24]. Subjects received either placebo 
(n = 188), 6 Amb a 1-U ragweed SLIT tablet (n = 190), 
or the marketed dose of 12 Amb a 1-U ragweed SLIT 
tablet (n = 187). Subjects were treated for 52  weeks, 
beginning 16 weeks before the start of the ragweed sea-
son (RS). During the RS, patients were provided with 
symptom-relieving medications used in a stepwise man-
ner according to symptom severity, including loratadine, 
olopatadine, mometasone and prednisone. The trial was 
initiated at 67 sites in the USA and at 13 sites in Canada. 
Similar to the GT-08 trial, subjects were asked to record 
daily symptoms and medication use in an electronic diary, 
assessed on the same scale as during the GT-08 trial. The 
RS was defined between the first of 3 consecutive days in 
which the ragweed pollen count was above the threshold 
of 10 grains/m3 and the last of three consecutive days 
in which the pollen count remained above the threshold.
The P05234 trial evaluated the efficacy and safety of 
the same SQ ragweed SLIT tablet and included an extra 
dosage arm [25]. In total, 784 subjects were randomised 
to placebo (n = 198) or one of three treatment groups: 
1.5 Amb a 1-U (n = 197), 6 Amb a 1-U (n = 195) or the 
marketed dose of 12 Amb a 1-U ragweed AIT (n = 194). 
The trial design for P05234 was the same as in P05233, 
including treatment period, pollen threshold, data collec-
tion and scoring. P05234 included 114 sites in the USA, 
Canada, Hungary, Ukraine and Russia. Table 1 presents 
the baseline characteristics for both trials.
2.2  Mapping Algorithm
The development of the two-part mapping algorithm from 
the weekly EQ-5D-3L data has been described in detail in 
the previous study [18]. The first part of the algorithm pre-
dicts the probability of (im)perfect health, and the second 
part predicts the disutility conditional on imperfect health. 
Covariates were chosen for inclusion in the model according 
to their expected clinical relevance and availability in both 
the GT-08 trial and the trial onto which the utilities were 
mapped. The final models were developed using longitudinal 
weekly EQ-5D-3L data and included the following covari-
ates: RQLQ score, daily symptom score, daily medication 
score, sex and asthma symptom score. All covariates in the 
algorithm were also available in each of the SQ ragweed 
SLIT tablet trials. This model was applied to the pooled 
data, and utilities were predicted using the regression equa-
tion coefficients presented in Table 2.
The first stage of the model predicts the probability of 
perfect health. The coefficients in Table 2 are in terms of 
log odds, so, to calculate the probability of perfect health, 
P(health), the inverse logit transformation was applied:
for a linear predictor xβ, where x represents a vector of 
observed covariates for a given patient at a given time point, 
and β represents the estimated coefficients from Table 2 such 
that:
For example, if a female (male = 0) subject reports a 
symptom score of 7, a medication score of 8, and an RQLQ 
score of 4.86, then the probability of perfect health on that 
day is 0.013, which corresponds to a 1 − 0.013 = 0.987 prob-
ability of imperfect health.
In the second stage of the model, EQ-5D-3L disutilities, 
d, were estimated from the coefficients of a linear mixed 
model and therefore predicted directly as:
In the observation described above, the subject also 
reported an asthma symptom score of 0, so the predicted 
disutility was 0.375. The results of both stages were used to 
calculate utility conditional on imperfect health:
Predicted utilities were calculated for each day of the RS 
for each treatment arm. In this analysis, QALYs and utili-
ties were analysed over the range of relative days with at 
least one EQ-5D-3L response in each treatment arm within 
the RS to accurately capture the utility difference during 
the RS. The difference in QALDs between treatment arms 
was calculated by multiplying the mean utility difference by 
the number of days over which the utilities were averaged. 
Only subjects at the marketed highest dosage level (12 Amb 
a 1-U) were included in this analysis. Days were counted 
relative to the first day of the pollen season, and day 0 of 
the analysis was the first day of the RS, which varied by 
geographic region of pollen exposure.
3  Results
The algorithm was applied to pooled SQ ragweed SLIT tab-
let trial data to predict EQ-5D-3L utilities. Figure 1 shows 
the predicted pooled mean utilities by treatment. The utilities 






x = 0.623 ∗ Male − 0.069 ∗ DSS − 0.070 ∗ DMS
+ 0.010 ∗ (DSS × DMS) − 1.869 ∗ RQLQ score
+ 4.587.
d = −0.003 ∗ DSS − 0.002 ∗ DMS
+ 0.0004 ∗ (DSS × DMS)
+ 0.015 ∗ Asthma Symptom Score
+ 0.051 ∗ RQLQ Score + 0.141.
u = 1 − P(imperfect health) ∗ d = 1 − 0.987 ∗ 0.375 = 0.630.
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trials. The figure shows a clear separation between treatment 
arms, a difference that is most pronounced at the peak of the 
pollen season.
The mean utility difference and QALDs were calculated 
between relative days 0 and 75. At least one pollen region 
had a duration of 76 days, though many were shorter. This 
method ensured that all data points collected within the RS 
were considered in the calculation. The mean utility differ-
ence between the SQ ragweed SLIT tablet and placebo was 
0.025 [95% confidence interval (CI) 0.011–0.038]. QALDs 
were calculated by multiplying the difference in pooled mean 
utility by the length of the season of interest. The SQ ragweed 
SLIT tablet showed an incremental QALD benefit of 1.900 
(95% CI 0.835–2.916) (Table 3).
Table 1  Baseline characteristics of SQ grass SLIT tablet and SQ ragweed SLIT tablet analytic sets
RQLQ Rhinoconjunctivitis Quality of Life Questionnaire, SD standard deviation, SLIT sublingual immunotherapy, SQ standardised quality






















12 Amb a 1-U 
(n = 374)
Sex, n (%)
 Male 167 (61) 164 (59) 93 (51) 75 (41) 100 (51) 102 (53) 193 (51) 177 (47)
 Female 109 (39) 113 (41) 91 (49) 108 (59) 96 (49) 89 (47) 187 (49) 197 (53)
Age
 Mean ± SD 34.3 ± 10.1 34.2 ± 9.5 36.0 ± 9.2 34.8 ± 9.4 36.7 ± 8.5 35.7 ± 8.8 36.3 ± 8.9 32.3 ± 9.1
 Median (Q1; 
Q3)
33 (27; 40) 33 (27; 39) 37 (29; 44) 36 (27; 44) 38 (30; 44) 37 (29; 44) 38 (30; 44) 36 (28; 44)
Rhinitis symptom score
 Mean ± SD 2.8 ± 3.4 2.0 ± 2.8 4.2 ± 4.0 3.6 ± 3.4 3.6 ± 3.8 3.0 ± 3.3 3.4 ± 3.9 3.3 ± 3.4
 Median (Q1; 
Q3)
2 (0; 5) 0 (0; 3) 3 (1; 6) 3 (1; 6) 3 (0; 6) 2 (0; 5) 3 (0; 6) 2 (0; 5)
Medication score
 Mean ± SD 2.1 ± 4.0 1.5 ± 3.3 1.5 ± 3.8 0.94 ± 3.0 1.8 ± 4.2 1.7 ± 3.3 1.7 ± 4.0 1.1 ± 3.1
 Median (Q1; 
Q3)
0 (0; 3) 0 (0; 0) 0 (0; 0) 0 (0; 0) 0 (0; 0) 0 (0; 0) 0 (0; 0) 0 (0; 0)
Asthma symptom score
 Mean ± SD 0.3 ± 0.9 0.2 ± 0.8 0.47 ± 1.2 0.37 ± 0.91 0.4 ± 1.1 0.4 ± 1.0 0.4 ± 1.1 0.4 ± 0.9
 Median (Q1; 
Q3)
0 (0; 0) 0 (0; 0) 0 (0; 0) 0 (0; 0) 0 (0; 0) 0 (0; 0) 0 (0; 0) 0 (0; 0)
History of asthma, n (%)
 Yes 33 (12) 43 (15) 43 (23) 42 (23) 32 (16) 36 (19) 75 (20) 78 (21)
 No 125 (45) 145 (52) 141 (77) 141 (77) 164 (84) 155 (80) 305 (80) 296 (79)
 Missing 118 (43) 89 (32) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
RQLQ score
 Mean ± SD 0.91 ± 1.0 0.69 ± 0.9 1.4 ± 1.3 1.2 ± 1.1 1.1 ± 1.2 0.98 ± 1.1 1.3 ± 1.2 1.07 ± 1.1
 Median (Q1; 
Q3)
1 (0; 1.1) 0.61 (1; 1) 1.1 (0.4; 2.2) 0.89 (0.3; 1.8) 0.79 (0.1; 1.8) 0.64 (0.1; 1.5) 1.0 (0.3; 2.0) 0.75 (0.14; 
1.64)
Table 2  Allergic rhinitis mapping function to EQ-5D-3L
EQ-5D-3L three-level EuroQoL 5-Dimensions instrument, RQLQ 
Rhinoconjunctivitis Quality of Life Questionnaire
Variable Stage 1 Stage 2
Coefficient p value Coefficient p value
Male 0.623 0.009 – –
Rhinitis symptom score − 0.069 < 0.001 − 0.003 0.011




0.010 < 0.001 0.0004 0.001
Asthma symptom score – – 0.015 < 0.001
RQLQ score − 1.869 < 0.001 0.051 < 0.001
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4  Discussion
This study provides evidence that immunotherapy improves 
quality of life in patients with seasonal ragweed allergies 
and generates utilities for use in cost-effectiveness studies. 
Although mapping functions exist for chronic rhinosinusi-
tis and asthma condition-specific measures, the algorithm 
developed in the previous study is the first to map RQLQ 
onto EQ-5D-3L utilities in AR [26, 27]. The results of the 
current study validate the previously developed algorithm, 
suggesting that the mapping algorithm may be applied to SQ 
ragweed SLIT tablet trials in addition to the SQ tree SLIT 
tablet trial in the previous study.
A key limitation in this analysis is the assumption that 
grass pollen allergy and ragweed pollen allergy have the 
same relationship with EQ-5D-3L utilities and other key 
covariates in the mapping algorithm. This assumption is 
supported by the fact that both grass and ragweed pollen 
are seasonal allergies and induce similar AR symptoms, such 
as itchy eyes, runny eyes, sneezing and blocked nose [7, 
25, 28]. The trials are also similar in terms of the patient 
population, exclusion criteria and baseline characteristics. 
The sex balance was slightly better in the SQ ragweed SLIT 
tablet trials, and 5% more subjects reported a history of 
asthma. Both trials asked subjects to rate AR symptoms 
and medication use on the same scale. Symptom scores are 
approximately one point higher in the SQ ragweed SLIT 
tablet trials, indicating more severe symptoms in both treat-
ment arms.
One difference between GT-08 and the SQ ragweed SLIT 
tablet trials was the specific medications available to subjects 
during the trials, although they are in the same drug class. 
In the GT-08 trial, subjects were offered symptom-reliev-
ing medications that included desloratadine, olopatadine, 
budesonide and prednisone to relieve residual symptoms. 
Subjects in the SQ ragweed SLIT tablet trials were offered 
loratadine, olopatadine, mometasone and prednisone. Both 
trials used these medications in a stepwise manner to control 
symptoms: first, an antihistamine, followed by an intranasal 
corticosteroid and then an oral corticosteroid. Asthma res-
cue medications were also allowed, though they were not 
included in the medication score. The AR medication use 
in both trials was rated on a 36-point scale in which each 
medication was weighted according to its estimated impact 
on allergy symptoms. Medication scores in the SQ ragweed 
SLIT tablet trials were lower by approximately half a point 
on a 36-point scale. The locations of the trial sites also dif-
fered between the two studies. The GT-08 study included 
sites in seven European countries, and the SQ ragweed SLIT 
tablet studies included sites in the USA, Canada, Hungary, 
Fig. 1  Pooled P05233 and 
P05234—mean daily utilities 
and pollen counts
Table 3  Pooled utilities and QALDs (days 0–75)
CI confidence interval, QALDs quality-adjusted life-days, SE standard 
error
Estimate SE (95% CI)
12 Amb a 1-U average utility 0.949
Placebo average utility 0.924
Mean utility difference 0.025 0.007 (0.011–0.038)
QALDs 1.900 0.531 (0.835–2.916)
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Ukraine and Russia. Patients were exposed to differing levels 
of pollen across sites.
The trials also had different treatment durations. Subjects 
in the GT-08 trial were treated for 3 years and followed for 
2 years after treatment discontinuation, whereas subjects 
in the SQ ragweed SLIT tablet trials were treated for an 
average of 52 weeks. The European Academy of Allergy 
and Clinical Immunology guidelines for allergy treatment 
recommend at least 3 years of AIT treatment to achieve a 
long-term treatment effect and improvement in quality of life 
[29]. Additional treatment and follow-up is needed to assess 
long-term improvement in quality of life.
5  Conclusions
Application of a previously developed mapping function 
allowed for the calculation of QALDs associated with the 
SQ ragweed SLIT tablet. The mapping function was devel-
oped in a previous study based on a grass pollen trial and 
applied in this analysis to two pooled SQ ragweed SLIT 
tablet trials, validating the use of the algorithm in other sea-
sonal pollen allergies. Although there were differences in 
baseline characteristics and types of supplementary medi-
cations used in the trials, these differences are minor, and 
application of the mapping function was appropriate. The 
results of the mapping showed a significant QALD benefit 
of the SQ ragweed SLIT tablet in the pooled P05233 and 
P05234 trials in the treatment of ragweed pollen-induced 
AR.
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